AveXis Inc. (AVXS) PT Raised to $58.00 at Jefferies Group
A number of other brokerages have also issued reports on AVXS. Wells Fargo & Co. upgraded shares of AveXis from a market perform rating to an outperform rating in a research report on Wednesday, August 17th. Zacks Investment Research upgraded shares of AveXis from a sell rating to a hold rating in a research report on Wednesday, June 15th. BMO Capital Markets reiterated an outperform rating and set a $52.00 target price on shares of AveXis in a research report on Monday, October 10th. Finally, Chardan Capital reiterated a buy rating and set a $60.00 target price on shares of AveXis in a research report on Friday, August 12th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $52.80.
Shares of AveXis (NASDAQ:AVXS) opened at 46.98 on Wednesday. The stock’s market cap is $1.08 billion. The company has a 50 day moving average of $41.16 and a 200 day moving average of $36.72. AveXis has a 12 month low of $17.40 and a 12 month high of $50.19.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.68) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.77) by $0.09. Equities research analysts expect that AveXis will post ($3.30) earnings per share for the current fiscal year.
In related news, insider Paul B. Manning sold 289,855 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $34.50, for a total transaction of $9,999,997.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Large investors have recently bought and sold shares of the company. American International Group Inc. acquired a new stake in AveXis during the second quarter worth $106,000. Nationwide Fund Advisors acquired a new stake in AveXis during the second quarter worth $120,000. TD Asset Management Inc. acquired a new stake in AveXis during the second quarter worth $259,000. Teachers Advisors Inc. increased its stake in AveXis by 74.1% in the second quarter. Teachers Advisors Inc. now owns 7,524 shares of the company’s stock worth $286,000 after buying an additional 3,202 shares during the period. Finally, California State Teachers Retirement System increased its stake in AveXis by 2.4% in the second quarter. California State Teachers Retirement System now owns 10,138 shares of the company’s stock worth $385,000 after buying an additional 238 shares during the period. 54.46% of the stock is owned by institutional investors and hedge funds.
AveXis Company Profile
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.